Evaluating Values-based Motivational Interviewing to Increase Treatment Completion With Fixed Dose Combination MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders and Treatment-naïve Genotype 1 Chronic Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms VBMI SUD/HCV
- 31 Jul 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.
- 31 Jul 2017 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.